STOCK TITAN
  1. Home
  2. Sec-filings
  3. PVLA
  4. [Form 4] PALVELLA THERAPEUTICS, INC. Insider Trading Activity

Palvella (PVLA) COO sells 4,302 shares under Rule 10b5-1 plan

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

Palvella Therapeutics, Inc. Chief Operating Officer Kathleen Goin exercised stock options and sold shares in pre-planned trades. On April 15, 2026, she exercised options for 2,154 shares of common stock at $7.14 per share and 2,148 shares at $9.08 per share, acquiring a total of 4,302 shares.

That same day, she executed open-market sales totaling 4,302 shares of common stock in multiple transactions, at weighted average prices including $125.9647, $127.1254, $128.2349, $129.1692, and $130.33 per share, with underlying trade ranges from $125.53 to $129.70 as disclosed. The filing states these transactions were carried out under a Rule 10b5-1 trading plan adopted on August 19, 2025 during an open trading window. After these transactions, the report shows 0 shares of common stock held directly by Goin, and no remaining option positions are listed.

Positive

  • None.

Negative

  • None.
Insider Goin Kathleen
Role Chief Operating Officer
Sold 4,302 shs ($547K)
Type Security Shares Price Value
Exercise Stock Option (Right to Buy) 2,154 $0.00 --
Exercise Stock Option (Right to Buy) 2,148 $0.00 --
Exercise Common Stock 2,154 $7.14 $15K
Exercise Common Stock 2,148 $9.08 $20K
Sale Common Stock 1,502 $125.9647 $189K
Sale Common Stock 1,500 $127.1254 $191K
Sale Common Stock 561 $128.2349 $72K
Sale Common Stock 639 $129.1692 $83K
Sale Common Stock 100 $130.33 $13K
Holdings After Transaction: Stock Option (Right to Buy) — 12,935 shares (Direct); Common Stock — 2,154 shares (Direct)
Footnotes (1)
  1. The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $125.53 to $126.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $126.77 to $127.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $127.88 to $128.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $128.95 to $129.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected. The stock option is fully vested.
Options exercised at $7.14 2,154 shares Stock options for common stock exercised at $7.14 per share on April 15, 2026
Options exercised at $9.08 2,148 shares Stock options for common stock exercised at $9.08 per share on April 15, 2026
Total shares sold 4,302 shares Open-market sales of common stock reported on April 15, 2026
Weighted average sale prices $125.9647–$130.33 per share Reported per-line weighted average prices for April 15, 2026 sales
Post-transaction common holdings 0 shares Total common stock directly owned by Kathleen Goin after reported transactions
Rule 10b5-1 plan adoption date August 19, 2025 Date the pre-arranged trading plan governing these trades was adopted
Rule 10b5-1 trading plan regulatory
"The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025."
A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.
Stock Option (Right to Buy financial
"security_title": "Stock Option (Right to Buy)""
weighted average price financial
"The price reported in Column 4 is a weighted average price."
Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.
open-market sale financial
"transaction_action": "open-market sale""
An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.
fully vested financial
"The stock option is fully vested."
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
X
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
Goin Kathleen
(Last)(First)(Middle)
C/O PALVELLA THERAPEUTICS, INC.
353 W. LANCASTER AVENUE, SUITE 200
(Street)
WAYNE PENNSYLVANIA 19087
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
PALVELLA THERAPEUTICS, INC. [ PVLA ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
Director10% Owner
XOfficer (give title below)Other (specify below)
Chief Operating Officer
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
04/15/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Common Stock04/15/2026M(1)2,154A$7.142,154D
Common Stock04/15/2026M(1)2,148A$9.084,302D
Common Stock04/15/2026S(1)1,502D$125.9647(2)2,800D
Common Stock04/15/2026S(1)1,500D$127.1254(3)1,300D
Common Stock04/15/2026S(1)561D$128.2349(4)739D
Common Stock04/15/2026S(1)639D$129.1692(5)100D
Common Stock04/15/2026S(1)100D$130.330D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$7.1404/15/2026M(1)2,154 (6)10/29/2029Common Stock2,154$012,935D
Stock Option (Right to Buy)$9.0804/15/2026M(1)2,148 (6)10/14/2030Common Stock2,148$012,888D
Explanation of Responses:
1. The transactions reported by the Reporting Person were effected pursuant to a Rule 10b5-1 trading plan adopted on August 19, 2025. The plan was adopted during an open trading window, at a time when the Reporting Person was not in possession of material non-public information and was reviewed and approved in accordance with the Issuer's Insider Trading Policy. The Issuer's officers and directors from time to time utilize trading plans to transact in its securities for reasons such as satisfying vesting-related income tax requirements, investment diversification, or other personal reasons.
2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $125.53 to $126.52, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
3. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $126.77 to $127.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
4. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $127.88 to $128.78, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
5. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $128.95 to $129.70, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price at which the transactions were effected.
6. The stock option is fully vested.
/s/ Kathleen A. McGowan, Attorney-in-Fact04/17/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Palvella Therapeutics (PVLA) COO Kathleen Goin report in this Form 4?

Kathleen Goin reported exercising stock options to acquire 4,302 Palvella Therapeutics common shares, then selling 4,302 shares in open-market transactions. All trades occurred on April 15, 2026 and were executed under a pre-arranged Rule 10b5-1 trading plan.

How many Palvella Therapeutics (PVLA) shares did the COO sell and at what prices?

The COO sold 4,302 Palvella Therapeutics common shares in multiple open-market trades. Weighted average prices disclosed include $125.9647, $127.1254, $128.2349, $129.1692, and $130.33 per share, with underlying trade ranges from $125.53 to $129.70.

Were Kathleen Goin’s Palvella (PVLA) share sales made under a Rule 10b5-1 trading plan?

Yes. The filing states the transactions were effected under a Rule 10b5-1 trading plan adopted on August 19, 2025. It notes the plan was set up during an open trading window, when she was not in possession of material non-public information.

How many Palvella Therapeutics (PVLA) shares does the COO hold after these transactions?

After the reported transactions, the Form 4 shows Kathleen Goin directly holding 0 shares of Palvella Therapeutics common stock. The derivative summary section in the filing shows no remaining stock options or other derivative positions associated with this report.

What stock options did Palvella (PVLA) COO Kathleen Goin exercise in this Form 4?

She exercised two stock option grants: one for 2,154 shares of common stock at a $7.14 exercise price and another for 2,148 shares at a $9.08 exercise price. The filing notes that the referenced stock option is fully vested.

What is the significance of the weighted average prices in the Palvella (PVLA) Form 4?

Weighted average prices summarize multiple trades executed within a price range for each sale line. The filing explains that underlying trades occurred in ranges from $125.53 to $129.70 per share and offers to provide detailed breakdowns of share counts at each separate price upon request.